# SymBio Pharmaceuticals clinical trials: 25 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 25 trials with SymBio Pharmaceuticals as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by SymBio Pharmaceuticals: 25 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/symbio-pharmaceuticals

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 25
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 25 newest of 25, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| February 4, 2026 | NCT07387367 | A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT | SymBio Pharmaceuticals | Phase 3 | Recruiting | Adenovirus Infections | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07387367) |
| January 7, 2025 | NCT06761677 | A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal... | SymBio Pharmaceuticals | Phase 1/2 | Suspended | Relapsed or Refractory Lymphoma Including ENKL | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06761677) |
| August 23, 2022 | NCT05511779 | Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation | SymBio Pharmaceuticals | Phase 2 | Terminated | BK Virus Infection, Nephropathy, Kidney Transplantation | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05511779) |
| January 13, 2021 | NCT04706923 | A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection | SymBio Pharmaceuticals | Phase 2 | Completed | Adenovirus Infections, Cytomegalovirus Infection | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04706923) |
| September 9, 2020 | NCT04542252 | Drug-Drug Interaction Study of Intravenous Administration of SyB V-1901 and Cyclosporine in Japanese Healthy Subjects | SymBio Pharmaceuticals | Phase 1 | Completed | Drug Drug Interaction | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04542252) |
| April 21, 2020 | NCT04354402 | Follow-up Study of SyB L-0501 in Combination With Rituximab to Treat DLBCL | SymBio Pharmaceuticals | Observational | Completed | Diffuse Large B Cell Lymphoma | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04354402) |
| April 3, 2019 | NCT03900377 | Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma | SymBio Pharmaceuticals | Phase 1/2 | Completed | Lymphoma, B-cell, Diffuse | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03900377) |
| July 27, 2018 | NCT03604679 | SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors | SymBio Pharmaceuticals | Phase 1 | Completed | Advanced Solid Tumor | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03604679) |
| April 11, 2018 | NCT03495167 | Study of SyB C-1101 in Patients With Myelodysplastic Syndrome | SymBio Pharmaceuticals | Phase 1 | Completed | Myelodysplastic Syndrome | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03495167) |
| December 14, 2017 | NCT03372837 | Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma | SymBio Pharmaceuticals | Phase 3 | Completed | Assess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCL | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03372837) |
| December 30, 2016 | NCT03005899 | Study of SyB P-1501 (Fentanyl HCI) for Treatment of Postoperative Pain | SymBio Pharmaceuticals | Phase 3 | Terminated | Postoperative Pain | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03005899) |
| May 26, 2016 | NCT02783547 | Combination Therapy of SyB C-1101 and Azacytidine in Patients With Myelodysplastic Syndrome | SymBio Pharmaceuticals | Phase 1 | Withdrawn | Myelodysplastic Syndrome | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02783547) |
| January 23, 2014 | NCT02042911 | Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic Leukemia | SymBio Pharmaceuticals | Phase 2 | Completed | Chronic Lymphocytic Leukemia | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02042911) |
| December 17, 2013 | NCT02014051 | Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) | SymBio Pharmaceuticals | Phase 1 | Completed | Myelodysplastic Syndrome | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02014051) |
| December 6, 2013 | NCT02002936 | Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study | SymBio Pharmaceuticals | Phase 1 | Completed | Myelodysplastic Syndrome | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02002936) |
| December 3, 2013 | NCT02000154 | Long Term Safety Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study | SymBio Pharmaceuticals | Phase 1 | Completed | Myelodysplastic Syndrome | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02000154) |
| May 9, 2013 | NCT01849848 | Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma | SymBio Pharmaceuticals | Phase 2 | Completed | Relapsed/Refractory Multiple Myeloma | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01849848) |
| October 31, 2012 | NCT01718691 | Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma... | SymBio Pharmaceuticals | Phase 2 | Completed | Low-grade B Cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma Where Hematopoietic Stem Cell Transplantation is Not... | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01718691) |
| October 4, 2012 | NCT01700335 | Safety and Pharmacokinetics Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) | SymBio Pharmaceuticals | Phase 1 | Completed | Myelodysplastic Syndrome | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01700335) |
| October 4, 2012 | NCT01700140 | Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV) | SymBio Pharmaceuticals | Phase 2 | Completed | Radiotherapy-induced Nausea and Vomiting (RINV) | 189 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01700140) |
| August 11, 2010 | NCT01179490 | Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma | SymBio Pharmaceuticals | Phase 2 | Terminated | Multiple Myeloma | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01179490) |
| May 7, 2010 | NCT01118845 | Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma | SymBio Pharmaceuticals | Phase 2 | Completed | Non-Hodgkin's Lymphoma, Lymphoma, Large Cell, Diffuse, Mantle Cell Lymphoma, Lymphoma, Follicular Lymphoma, Large... | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01118845) |
| November 20, 2008 | NCT00794638 | A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma | SymBio Pharmaceuticals | Phase 1 | Completed | Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00794638) |
| February 11, 2008 | NCT00612183 | Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma | SymBio Pharmaceuticals | Phase 2 | Completed | Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00612183) |
| October 17, 2006 | NCT00389051 | A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-cell Non-Hodgkin's Lymphoma | SymBio Pharmaceuticals | Phase 1 | Completed | Non-Hodgkin's Lymphoma | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00389051) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 10 |
| Phase 1/2 | 2 |
| Phase 2 | 9 |
| Phase 3 | 3 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 19 |
| Terminated | 3 |
| Recruiting | 1 |
| Suspended | 1 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Myelodysplastic Syndromes | 6 |
| Lymphoma, Non-Hodgkin | 4 |
| Lymphoma, Large B-Cell, Diffuse | 4 |
| Lymphoma | 4 |
| Lymphoma, Mantle-Cell | 3 |
| Lymphoma, Follicular | 2 |
| Adenoviridae Infections | 2 |
| Multiple Myeloma | 2 |
| Recurrence | 1 |
| Epstein-Barr Virus Infections | 1 |
| Immunoblastic Lymphadenopathy | 1 |
| Lymphoma, T-Cell | 1 |
| Lymphoma, Large-Cell, Anaplastic | 1 |
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 |
| Leukemia-Lymphoma, Adult T-Cell | 1 |
| Cytomegalovirus Infections | 1 |
| Vomiting | 1 |
| Kidney Diseases | 1 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 |
| Dendritic Cell Sarcoma, Interdigitating | 1 |
| Pain, Postoperative | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Taiwanese restaurants in the United States](https://specstream.ai/data/businesses/taiwanese-restaurants/united-states)
- [Cosmetic products manufacturers in the United States](https://specstream.ai/data/businesses/cosmetic-products-manufacturers/united-states)
- [Metal fabricators in the United States](https://specstream.ai/data/businesses/metal-fabricators/united-states)
- [Web hosting companies in the United States](https://specstream.ai/data/businesses/web-hosting-companies/united-states)
- [Energy management companies in the United States](https://specstream.ai/data/businesses/energy-management-companies/united-states)
